Figure 1
Figure 1. Two-year cumulative incidence of CCyR, MR3, and CMR4.5 according to the 3-month BCR-ABL1 transcript level. (A-B) The cumulative incidence of CCyR according to whether the transcript level is > or < 10% (A) or 2.26% (B). (C-D) The cumulative incidence of MR3 according to whether the transcript level is > or < 10% (C) or 0.92% (D). (E-F) The cumulative incidence of MR4.5 according to whether the transcript level is > or < 10% (E) or 0.57% (F). The 2.26%, 0.92%, and 0.57% are the transcript level cut-offs identified using the receiver operating characteristic curves that optimally predict for each specific outcome.

Two-year cumulative incidence of CCyR, MR3, and CMR4.5 according to the 3-month BCR-ABL1 transcript level. (A-B) The cumulative incidence of CCyR according to whether the transcript level is > or < 10% (A) or 2.26% (B). (C-D) The cumulative incidence of MR3 according to whether the transcript level is > or < 10% (C) or 0.92% (D). (E-F) The cumulative incidence of MR4.5 according to whether the transcript level is > or < 10% (E) or 0.57% (F). The 2.26%, 0.92%, and 0.57% are the transcript level cut-offs identified using the receiver operating characteristic curves that optimally predict for each specific outcome.

Close Modal

or Create an Account

Close Modal
Close Modal